AZN · NKTR 10-KMar 13 '26
“Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.”
PFE · NKTR 10-KMar 13 '26
“Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.”
AZN · AXSM 10-KFeb 23 '26
“We also assumed the AZD7325 license agreement between Baergic and AZ.”
PFE · AXSM 10-KFeb 23 '26
“In January 2020, the Company entered into an exclusive license agreement with Pfizer Inc. ("Pfizer") for Pfizer's clinical and non-clinical data, and intellectual property for reboxetine, the active pharmaceutical ingredient in AXS-12 which the Company is developing for the treatment of narcolepsy.”
AZN · AAPG 20-FApr 29 '26
“We have also established collaborations and other relationships with leading biotechnology and pharmaceutical companies around the world, including a collaboration and license agreement with Innovent and clinical collaboration agreements with AstraZeneca, Merck, and Pfizer”
PFE · AAPG 20-FApr 29 '26
“We have also established collaborations and other relationships with leading biotechnology and pharmaceutical companies around the world, including a collaboration and license agreement with Innovent and clinical collaboration agreements with AstraZeneca, Merck, and Pfizer”